Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.

摘要: BACKGROUND: The transmembrane glycoprotein CD133 (cluster of differentiation 133; also known as Prominin or PROM1) has been described a potential stem cell marker in colorectal cancer and is associated with higher tumorigenic resistance to radiochemotherapy (RCT). In this study, expression was evaluated pre-RCT tumor biopsies the corresponding post-RCT surgical specimens from patients locally advanced rectal adenocarcinoma, levels were correlated histopathologic features clinical follow-up. METHODS: One hundred twenty-six International Union Against Cancer (UICC) stage II/III who received preoperative 5-fluorouracil (5-FU)-based RCT within German Rectal Trials investigated. Pre-RCT determined using immunohistochemistry parameters, regression grade, recurrence, patient survival. RESULTS: Compared biopsies, significantly observed (P = .01). However, no correlations for either between levels, characteristics, survival. matched analyses biopsy/tumor pairs, had an increased fraction CD133-expressing (CD133+) cells after residual stages .02) lower < Moreover, these reduced disease-free survival cancer-specific overall univariate analysis .001 P .004, respectively) multivariate .003 .024, respectively). CONCLUSIONS: The enrichment CD133+ during minor local response, distant decreased The current results indicate that up-regulation intratumoral expression, contrast absolute plays important role progression metastasis are receiving neoadjuvant RCT. 2013. © 2012 American Society.